Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
[google_news title=”” keyword=”macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Roche Pharma launches Vabysmo to treat vision impairmenton March 5, 2024 at 5:15 am
effectively targeting two pathways involved in the development of neovascular or "wet" age-related macular degeneration (nAMD) and diabetic macular edema (DME), both leading causes of vision ...
- Roche's new bispecific monoclonal antibody to treat vision loss in Indiaon March 5, 2024 at 5:02 am
Roche Pharma on Tuesday announced its foray into ophthalmology sector in India with a new bispecific monoclonal antibody (mAB) to treat vision loss.
- Risk of cancer and AMDon March 5, 2024 at 3:00 am
The investigators believe that AMD and cancer may have similar risk factors in common, thus suggesting that they have common pathogenic pathways.
- Management of Choroidal Neovascularization in Myopic Macular Degenerationon March 3, 2024 at 4:00 pm
Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...
- Macular Degeneration : What Is It & Treatmentson March 3, 2024 at 1:28 pm
Overview A vision impairment resulting from deterioration of the central part of retina, a thin layer at the back of the eye on the inner side. Symptoms Central vision loss, blurred vision, and ...
- How to Prevent Macular Degenerationon March 3, 2024 at 6:00 am
Medically reviewed by Johnstone M. Kim, MD Macular degeneration, or age-related macular degeneration (AMD), is a form of vision loss that affects your ability to see things in the center of your ...
- How do doctors test for macular degeneration?on February 26, 2024 at 4:00 pm
To diagnose macular degeneration, doctors can use the Amsler grid and other diagnostic tools to check the macula, the part of the retina at the back of the eye. Doctors may spot early symptoms ...
- How Is Macular Degeneration Diagnosed?on February 25, 2024 at 6:00 am
Macular degeneration, or age-related macular degeneration (AMD), is a progressive form of vision loss diagnosed using eye tests and imaging techniques.
- What Are the Early Warning Signs of Macular Degeneration?on February 24, 2024 at 6:02 am
With age-related macular degeneration (AMD), you can lose the detailed central vision you rely on for reading, recognizing faces, and navigating many life tasks. This occurs as the part of the eye ...
- Top 5 Best Eye Supplements for Macular Degeneration in 2024on February 23, 2024 at 4:00 pm
Macular degeneration is a prevalent eye disorder affecting millions globally. This progressive condition harms the macula, a tiny area in the retina responsible for central vision. As the illness ...
via Google News and Bing News